Description
ISM5939 is an experimental drug currently being studied in clinical trials. It is being investigated as a potential treatment for advanced or metastatic solid tumors, including colorectal cancer. The trials are in the early phase (Phase 1), primarily focused on determining the safe dosage and how the drug is processed by the body (pharmacokinetics) and its effects on the body (pharmacodynamics). Early results on how well it shrinks tumors (antitumor activity) are also being looked at. It is being tested alone (monotherapy) and potentially in combination with other cancer treatments like chemotherapy (cisplatin, docetaxel) and immunotherapy (pembrolizumab). Because it is still in early trials, its effectiveness and long-term side effects are not yet known.
Mechanism of Action
ISM5939 is a new drug, and the specific way it works (its mechanism of action) is still being investigated in clinical trials. Researchers are studying how it interacts with the body and its potential effects on tumor cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.